Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

Published On Oct 2, 2024, 3:41 PM

Cassava Sciences is facing scrutiny regarding its Alzheimer’s drug simufilam, with charges from the SEC over misleading clinical trial data. Despite retractions of supportive studies and multiple resignations within the company, simufilam remains in advanced clinical trials. Experts question why testing continues amidst the controversy, though Cassava maintains that some evidence still supports the drug's potential effectiveness.

Read full article

Stock Forecasts

SAVAView SAVA chart on TradingView

Negative

The ongoing controversies and SEC charges may lead to further stock price decline as investor confidence wavers. Potential delays or halts in clinical trials could weigh heavily on the stock.

Related News

Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

Oct 2, 2024, 3:41 PM

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.

SAVA